{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:28:21Z","timestamp":1769844501000,"version":"3.49.0"},"publisher-location":"Cham","reference-count":80,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030913342","type":"print"},{"value":"9783030913359","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/7854_2020_182","type":"book-chapter","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T15:55:54Z","timestamp":1613231754000},"page":"195-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["GABAB Receptors and Alcohol Use Disorders: Clinical Studies"],"prefix":"10.1007","author":[{"given":"Warren B.","family":"Logge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten C.","family":"Morley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Haber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,13]]},"reference":[{"key":"182_CR1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1527-3458.2007.00021.x","volume":"13","author":"CL Adams","year":"2007","unstructured":"Adams CL, Lawrence AJ (2007) CGP7930: a positive allosteric modulator of the GABAB receptor. CNS Drug Rev 13:308\u2013316","journal-title":"CNS Drug Rev"},{"key":"182_CR2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","volume":"37","author":"G Addolorato","year":"2002","unstructured":"Addolorato G, Caputo F, Capristo E et al (2002a) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37:504\u2013508","journal-title":"Alcohol Alcohol"},{"key":"182_CR3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0002-9343(01)01088-9","volume":"112","author":"G Addolorato","year":"2002","unstructured":"Addolorato G, Caputo F, Capristo E et al (2002b) Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med 112:226\u2013229","journal-title":"Am J Med"},{"key":"182_CR4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00002826-200309000-00010","volume":"26","author":"G Addolorato","year":"2003","unstructured":"Addolorato G, Leggio L, Abenavoli L et al (2003) Suppression of alcohol delirium tremens by baclofen administration: a case report. Clin Neuropharmacol 26:258","journal-title":"Clin Neuropharmacol"},{"key":"182_CR5","doi-asserted-by":"crossref","first-page":"276.e13","DOI":"10.1016\/j.amjmed.2005.08.042","volume":"119","author":"G Addolorato","year":"2006","unstructured":"Addolorato G, Leggio L, Abenavoli L et al (2006) Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 119:276.e13\u2013276.e18","journal-title":"Am J Med"},{"key":"182_CR6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","volume":"370","author":"G Addolorato","year":"2007","unstructured":"Addolorato G, Leggio L, Ferrulli A et al (2007) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370:1915\u20131922","journal-title":"Lancet"},{"key":"182_CR7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","volume":"46","author":"G Addolorato","year":"2011","unstructured":"Addolorato G, Leggio L, Ferrulli A et al (2011) Dose\u2013response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 46:312\u2013317","journal-title":"Alcohol Alcohol"},{"key":"182_CR8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fnins.2014.00140","volume":"8","author":"R Agabio","year":"2014","unstructured":"Agabio R, Colombo G (2014) GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Front Neurosci 8:140","journal-title":"Front Neurosci"},{"key":"182_CR9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","volume":"5","author":"R Agabio","year":"2018","unstructured":"Agabio R, Sinclair JMA, Addolorato G et al (2018) Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry 5:957\u2013960","journal-title":"Lancet Psychiatry"},{"key":"182_CR10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","volume":"40","author":"O Ameisen","year":"2004","unstructured":"Ameisen O (2004) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 40:147\u2013150","journal-title":"Alcohol Alcohol"},{"key":"182_CR11","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. Author, Washington"},{"key":"182_CR12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS (2019) Burden of liver diseases in the world. J Hepatol 70:151\u2013171","journal-title":"J Hepatol"},{"key":"182_CR13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bcp.2013.10.028","volume":"87","author":"T Bay","year":"2014","unstructured":"Bay T, Eghorn LF, Klein AB, Wellendorph P (2014) GHB receptor targets in the CNS: focus on high-affinity binding sites. Biochem Pharmacol 87:220\u2013228","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"182_CR14","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.euroneuro.2018.08.507","volume":"28","author":"A Beck","year":"2018","unstructured":"Beck A, Pelz P, Lorenz RC et al (2018) Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. Eur Neuropsychopharmacol 28(11):1206\u20131216","journal-title":"Eur Neuropsychopharmacol"},{"key":"182_CR15","first-page":"348","volume":"31","author":"HC Becker","year":"2008","unstructured":"Becker HC (2008) Alcohol dependence, withdrawal, and relapse. Alcohol Res Health 31:348\u2013361","journal-title":"Alcohol Res Health"},{"key":"182_CR16","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.euroneuro.2016.10.006","volume":"26","author":"EM Beraha","year":"2016","unstructured":"Beraha EM, Salemink E, Goudriaan AE et al (2016) Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol 26:1950\u20131959","journal-title":"Eur Neuropsychopharmacol"},{"key":"182_CR17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bcpt.12779","volume":"121","author":"D Boels","year":"2017","unstructured":"Boels D, Victorri-Vigneau C, Grall-Bronnec M et al (2017) Baclofen and alcohol-dependent patients: a real risk of severe self-poisoning. Basic Clin Pharmacol Toxicol 121:353\u2013359","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"182_CR18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/acps.12905","volume":"138","author":"T Bschor","year":"2018","unstructured":"Bschor T, Henssler J, M\u00fcller M, Baethge C (2018) Baclofen for alcohol use disorder\u2014a systematic meta-analysis. Acta Psychiatr Scand 138:232\u2013242","journal-title":"Acta Psychiatr Scand"},{"key":"182_CR19","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3390\/ijerph6061917","volume":"6","author":"F Caputo","year":"2009","unstructured":"Caputo F, Vignoli T, Maremmani I, Bernardi M, Zoli G (2009) Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health 6:1917\u20131929","journal-title":"Int J Environ Res Public Health"},{"key":"182_CR20","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0006-2952(99)00265-8","volume":"58","author":"CD Cash","year":"1999","unstructured":"Cash CD, Gobaille S, Kemmel V, Andriamampandry C, Maitre M (1999) \u03b3-Hydroxybutyrate receptor function studied by the modulation of nitric oxide synthase activity in rat frontal cortex punches. Biochem Pharmacol 58:1815\u20131819","journal-title":"Biochem Pharmacol"},{"key":"182_CR21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2515\/therapie\/2015027","volume":"70","author":"C Chaignot","year":"2015","unstructured":"Chaignot C, Weill A, Ricordeau P, Alla F (2015) Use in France of baclofen for alcohol dependence from 2007 to 2013: cohort study based on the databases SNIIRAM and PMSI. Therapie 70:443\u2013453","journal-title":"Therapie"},{"key":"182_CR22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(15)00122-1","volume":"387","author":"JP Connor","year":"2016","unstructured":"Connor JP, Haber PS, Hall WD (2016) Alcohol use disorders. Lancet 387:988\u2013998","journal-title":"Lancet"},{"key":"182_CR23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3389\/fpsyt.2018.00773","volume":"9","author":"G Cooney","year":"2019","unstructured":"Cooney G, Heydtmann M, Smith ID (2019) Baclofen and the alcohol withdrawal syndrome-a short review. Front Psych 9:773","journal-title":"Front Psych"},{"key":"182_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/adb.12314","volume":"21","author":"KE Courtney","year":"2016","unstructured":"Courtney KE, Schacht JP, Hutchison K, Roche DJO, Ray LA (2016) Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addict Biol 21:3\u201322","journal-title":"Addict Biol"},{"key":"182_CR25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ana.410170202","volume":"17","author":"RA Davidoff","year":"1985","unstructured":"Davidoff RA (1985) Antispasticity drugs: mechanisms of action. Ann Neurol 17:107\u2013116","journal-title":"Ann Neurol"},{"key":"182_CR26","first-page":"143","volume":"5","author":"R de Beaurepaire","year":"2014","unstructured":"de Beaurepaire R (2014) The use of very high-doses of baclofen for the treatment of alcohol-dependence: a case series. Front Psych 5:143\u2013143","journal-title":"Front Psych"},{"key":"182_CR27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/alcalc\/agr131","volume":"46","author":"GM Dore","year":"2011","unstructured":"Dore GM, Lo K, Juckes L, Bezyan S, Latt N (2011) Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series. Alcohol Alcohol 46:714\u2013720","journal-title":"Alcohol Alcohol"},{"key":"182_CR28","doi-asserted-by":"crossref","first-page":"e29369","DOI":"10.1371\/journal.pone.0029369","volume":"7","author":"M-A Enoch","year":"2012","unstructured":"Enoch M-A, Zhou Z, Kimura M, Mash DC, Yuan Q, Goldman D (2012) GABAergic gene expression in postmortem hippocampus from alcoholics and cocaine addicts; corresponding findings in alcohol-Na\u00efve P and NP rats. PLoS One 7:e29369","journal-title":"PLoS One"},{"key":"182_CR29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/acer.12929","volume":"40","author":"M-A Enoch","year":"2016","unstructured":"Enoch M-A, Hodgkinson CA, Shen P-H et al (2016) GABBR1 and SLC6A1, two genes involved in modulation of GABA synaptic transmission, influence risk for alcoholism: results from three ethnically diverse populations. Alcohol Clin Exp Res 40:93\u2013101","journal-title":"Alcohol Clin Exp Res"},{"key":"182_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1530-0277.2008.00805.x","volume":"33","author":"SM Evans","year":"2009","unstructured":"Evans SM, Bisaga A (2009) Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res 33:19\u201330","journal-title":"Alcohol Clin Exp Res"},{"key":"182_CR31","doi-asserted-by":"crossref","first-page":"e1108","DOI":"10.1038\/tp.2017.71","volume":"7","author":"M Farokhnia","year":"2017","unstructured":"Farokhnia M, Schwandt ML, Lee MR et al (2017) Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry 7:e1108","journal-title":"Transl Psychiatry"},{"key":"182_CR32","doi-asserted-by":"publisher","unstructured":"Farokhnia M, Deschaine SL, Sadighi A et al (2018a) A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-018-0287-y","DOI":"10.1038\/s41380-018-0287-y"},{"key":"182_CR33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.neuropharm.2018.04.011","volume":"137","author":"M Farokhnia","year":"2018","unstructured":"Farokhnia M, Sheskier MB, Lee MR et al (2018b) Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: results from a combined outpatient and human laboratory experiment. Neuropharmacology 137:230\u2013239","journal-title":"Neuropharmacology"},{"key":"182_CR34","first-page":"83","volume":"23","author":"DA Fiellin","year":"2002","unstructured":"Fiellin DA, O\u2019Connor PG, Holmboe ES, Horwitz RI (2002) Risk for delirium tremens in patients with alcohol withdrawal syndrome. Subst Abus 23:83\u201394","journal-title":"Subst Abus"},{"key":"182_CR35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/imj.13237","volume":"46","author":"CH Freyer","year":"2016","unstructured":"Freyer CH, Morley KC, Haber PS (2016) Alcohol use disorders in Australia. Intern Med J 46:1259\u20131268","journal-title":"Intern Med J"},{"key":"182_CR36","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","volume":"34","author":"JC Garbutt","year":"2010","unstructured":"Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA (2010) Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 34:1849\u20131857","journal-title":"Alcohol Clin Exp Res"},{"key":"182_CR37","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","volume":"152","author":"D Goldberg","year":"2017","unstructured":"Goldberg D, Ditah IC, Saeian K et al (2017) Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 152:1090\u201399.e1","journal-title":"Gastroenterology"},{"key":"182_CR38","first-page":"60","volume":"61","author":"P Gulati","year":"2019","unstructured":"Gulati P, Chavan B, Sidana A (2019) Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. Indian J Psychiatry 61:60\u201364","journal-title":"Indian J Psychiatry"},{"key":"182_CR39","volume-title":"Guidelines for the treatment of alcohol problems","author":"P Haber","year":"2009","unstructured":"Haber P, Lintzeris N, Proude E, Lopatko O (2009) Guidelines for the treatment of alcohol problems. Department of Health and Ageing, Canberra"},{"key":"182_CR40","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","volume":"112","author":"P Hauser","year":"2017","unstructured":"Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E (2017) The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction 112:1173\u20131183","journal-title":"Addiction"},{"key":"182_CR41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/16066359.2018.1493104","volume":"27","author":"DB Heppe","year":"2019","unstructured":"Heppe DB, Keniston A, Bendelow T et al (2019) Reducing the severity of alcohol withdrawal with oral baclofen: a randomized controlled trial. Addict Res Theory 27:220\u2013225","journal-title":"Addict Res Theory"},{"key":"182_CR42","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/1060028014520882","volume":"48","author":"A Hetland","year":"2014","unstructured":"Hetland A, Carr DB (2014) Medications and impaired driving. Ann Pharmacother 48:494\u2013506","journal-title":"Ann Pharmacother"},{"key":"182_CR43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.9758\/cpn.2018.16.3.290","volume":"16","author":"B Holla","year":"2018","unstructured":"Holla B, Karthik S, Biswal J et al (2018) Brain functional magnetic resonance imaging cue-reactivity can predict baclofen response in alcohol use disorders. Clin Psychopharmacol Neurosci 16:290\u2013301","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"182_CR44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/alcalc\/agy082","volume":"54","author":"N Jamshidi","year":"2018","unstructured":"Jamshidi N, Morley KC, Cairns R, Dawson A, Haber PS (2018) A review of baclofen overdoses in Australia: calls to a poisons information centre and a case series. Alcohol Alcohol 54:73\u201378","journal-title":"Alcohol Alcohol"},{"key":"182_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2013.10.013","volume":"38","author":"AJ Jasinska","year":"2014","unstructured":"Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y (2014) Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. Neurosci Biobehav Rev 38:1\u201316","journal-title":"Neurosci Biobehav Rev"},{"key":"182_CR46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcp.2007.08.005","volume":"75","author":"BA Johnson","year":"2008","unstructured":"Johnson BA (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75:34\u201356","journal-title":"Biochem Pharmacol"},{"key":"182_CR47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40261-013-0158-x","volume":"34","author":"GM Keating","year":"2014","unstructured":"Keating GM (2014) Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clin Drug Investig 34:63\u201380","journal-title":"Clin Drug Investig"},{"key":"182_CR48","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.biopsych.2013.08.028","volume":"75","author":"C Lee","year":"2014","unstructured":"Lee C, Mayfield RD, Harris RA (2014) Altered gamma-aminobutyric acid type B receptor subunit 1 splicing in alcoholics. Biol Psychiatry 75:765\u2013773","journal-title":"Biol Psychiatry"},{"key":"182_CR49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187152710790966614","volume":"9","author":"L Leggio","year":"2010","unstructured":"Leggio L, Garbutt J, Addolorato G (2010) Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets 9:33\u201344","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"182_CR50","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.pbb.2012.11.013","volume":"103","author":"L Leggio","year":"2013","unstructured":"Leggio L, Zywiak WH, McGeary JE et al (2013) A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol Biochem Behav 103:784\u2013791","journal-title":"Pharmacol Biochem Behav"},{"key":"182_CR51","first-page":"CD006266","volume":"2","author":"MA Leone","year":"2010","unstructured":"Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F (2010) Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev 2:CD006266","journal-title":"Cochrane Database Syst Rev"},{"key":"182_CR52","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2515\/therapie\/2014038","volume":"69","author":"N Lesouef","year":"2014","unstructured":"Lesouef N, Bellet F, Mounier G, Beyens M-N (2014) Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Therapie 69:427\u2013435","journal-title":"Therapie"},{"key":"182_CR53","first-page":"CD008502","volume":"8","author":"J Liu","year":"2019","unstructured":"Liu J, Wang LN (2019) Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 8:CD008502","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"182_CR54","doi-asserted-by":"crossref","first-page":"e2722","DOI":"10.1002\/hup.2722","volume":"35","author":"WB Logge","year":"2019","unstructured":"Logge WB, Baillie AJ, Haber PS, Morley KC (2019a) Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Hum Psychopharmacol Clin Exp 35(2):e2722","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"182_CR55","doi-asserted-by":"publisher","unstructured":"Logge WB, Morris RW, Baillie AJ, Haber PS, Morley KC (2019b) Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology. https:\/\/doi.org\/10.1007\/s00213-019-05192-5","DOI":"10.1007\/s00213-019-05192-5"},{"key":"182_CR56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jhm.928","volume":"6","author":"JE Lyon","year":"2011","unstructured":"Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM (2011) Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. J Hosp Med 6:469\u2013474","journal-title":"J Hosp Med"},{"key":"182_CR57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40263-018-0596-3","volume":"33","author":"P Maccioni","year":"2019","unstructured":"Maccioni P, Colombo G (2019) Potential of GABAB receptor positive allosteric modulators in the treatment of alcohol use disorder. CNS Drugs 33:107\u2013123","journal-title":"CNS Drugs"},{"key":"182_CR58","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","volume":"49","author":"KC Morley","year":"2014","unstructured":"Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS (2014) Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol 49:654\u2013660","journal-title":"Alcohol Alcohol"},{"key":"182_CR59","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.drugalcdep.2016.06.027","volume":"166","author":"KC Morley","year":"2016","unstructured":"Morley KC, Logge W, Pearson S-A, Baillie A, Haber PS (2016) National trends in alcohol pharmacotherapy: findings from an Australian claims database. Drug Alcohol Depend 166:254\u2013257","journal-title":"Drug Alcohol Depend"},{"key":"182_CR60","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","volume":"212","author":"KC Morley","year":"2018","unstructured":"Morley KC, Baillie A, Fraser I et al (2018a) Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. Br J Psychiatry 212:362\u2013369","journal-title":"Br J Psychiatry"},{"issue":"1","key":"182_CR61","first-page":"e1270","volume":"25","author":"KC Morley","year":"2018","unstructured":"Morley KC, Lagopoulos J, Logge W, Baillie A, Adams C, Haber PS (2018b) Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addict Biol 25(1):e1270","journal-title":"Addict Biol"},{"key":"182_CR62","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/add.14373","volume":"113","author":"KC Morley","year":"2018","unstructured":"Morley KC, Luquin N, Baillie A et al (2018c) Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction 113:2205\u20132213","journal-title":"Addiction"},{"key":"182_CR63","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","volume":"25","author":"CA M\u00fcller","year":"2015","unstructured":"M\u00fcller CA, Geisel O, Pelz P et al (2015) High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 25:1167\u20131177","journal-title":"Eur Neuropsychopharmacol"},{"key":"182_CR64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/00048674.2010.524622","volume":"45","author":"JJ Nasti","year":"2011","unstructured":"Nasti JJ, Brakoulias V (2011) Chronic baclofen abuse and withdrawal delirium. Aust N Z J Psychiatry 45:86\u201387","journal-title":"Aust N Z J Psychiatry"},{"key":"182_CR65","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","volume":"28","author":"M Pierce","year":"2018","unstructured":"Pierce M, Sutterland A, Beraha EM, Morley KC, van den Brink W (2018) Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol 28:795\u2013806","journal-title":"Eur Neuropsychopharmacol"},{"key":"182_CR66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsat.2014.11.007","volume":"52","author":"AM Ponizovsky","year":"2015","unstructured":"Ponizovsky AM, Rosca P, Aronovich E, Weizman A, Grinshpoon A (2015) Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. J Subst Abus Treat 52:24\u201330","journal-title":"J Subst Abus Treat"},{"key":"182_CR67","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/0253-7613.135947","volume":"46","author":"VK Reddy","year":"2014","unstructured":"Reddy VK, Girish K, Lakshmi P, Vijendra R, Kumar A, Harsha R (2014) Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Indian J Pharmacol 46:372\u2013377","journal-title":"Indian J Pharmacol"},{"key":"182_CR68","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2013.03.007","volume":"59","author":"J Rehm","year":"2013","unstructured":"Rehm J, Samokhvalov AV, Shield KD (2013) Global burden of alcoholic liver diseases. J Hepatol 59:160\u2013168","journal-title":"J Hepatol"},{"key":"182_CR69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/agx030","volume":"52","author":"M Reynaud","year":"2017","unstructured":"Reynaud M, Aubin H-J, Trinquet F et al (2017) A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients\u2014the ALPADIR study. Alcohol Alcohol 52:439\u2013446","journal-title":"Alcohol Alcohol"},{"key":"182_CR70","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.euroneuro.2015.05.008","volume":"25","author":"B Rolland","year":"2015","unstructured":"Rolland B, Labreuche J, Duhamel A et al (2015) Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol 25:1631\u20131636","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"182_CR71","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/alcalc\/agz082","volume":"55","author":"B Rolland","year":"2019","unstructured":"Rolland B, Simon N, Franchitto N, Aubin H-J (2019) France grants an approval to baclofen for alcohol dependence. Alcohol Alcohol 55(1):44\u201345","journal-title":"Alcohol Alcohol"},{"key":"182_CR72","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/alcalc\/agz026","volume":"54","author":"SA Rombouts","year":"2019","unstructured":"Rombouts SA, Baillie A, Haber PS, Morley KC (2019) Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol Alcohol 54:272\u2013278","journal-title":"Alcohol Alcohol"},{"key":"182_CR73","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14191","volume":"113","author":"AK Rose","year":"2018","unstructured":"Rose AK, Jones A (2018) Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction 113:1396\u20131406","journal-title":"Addiction"},{"key":"182_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/alcalc\/agq086","volume":"46","author":"RA Sewell","year":"2010","unstructured":"Sewell RA, Petrakis IL (2010) Does gamma-hydroxybutyrate (GHB) have a role in the treatment of alcoholism? Alcohol Alcohol 46:1\u20132","journal-title":"Alcohol Alcohol"},{"key":"182_CR75","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","volume":"84","author":"JT Sullivan","year":"1989","unstructured":"Sullivan JT, Kathy S, Joyce S, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84:1353\u20131357","journal-title":"Br J Addict"},{"key":"182_CR76","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","volume":"69","author":"M Thursz","year":"2018","unstructured":"Thursz M, Gual A, Lackner C et al (2018) EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol 69:154\u2013181","journal-title":"J Hepatol"},{"key":"182_CR77","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/adb.12645","volume":"23","author":"W van den Brink","year":"2018","unstructured":"van den Brink W, Addolorato G, Aubin H-J et al (2018) Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. Addict Biol 23:969\u2013986","journal-title":"Addict Biol"},{"key":"182_CR78","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/B978-0-12-800773-0.00020-3","volume-title":"Molecular aspects of alcohol and nutrition","author":"K Wang","year":"2016","unstructured":"Wang K, Wang L (2016) Chapter 20 \u2013 genes associated with alcohol withdrawal. In: Patel VB (ed) Molecular aspects of alcohol and nutrition. Academic Press, San Diego, pp 247\u2013259"},{"key":"182_CR79","volume-title":"Global status report on alcohol and health 2018","author":"World Health Organization","year":"2018","unstructured":"World Health Organization (2018a) Global status report on alcohol and health 2018. World Health Organization, Geneva"},{"key":"182_CR80","volume-title":"International classification of diseases for mortality and morbidity statistics","author":"World Health Organization","year":"2018","unstructured":"World Health Organization (2018b) International classification of diseases for mortality and morbidity statistics. World Health Organization, Geneva"}],"container-title":["Current Topics in Behavioral Neurosciences","Behavioral Neurobiology of GABAB Receptor Function"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2020_182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T04:50:18Z","timestamp":1697863818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2020_182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030913342","9783030913359"],"references-count":80,"URL":"https:\/\/doi.org\/10.1007\/7854_2020_182","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"13 February 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}